Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986166 in Healthy Males
NCT05409157Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of udifitimod in atopic dermatitis (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Total amount of total radioactivity (TRA) recovered in urine up to 90 days, Total amount of total radioactivity (TRA) recovered in feces up to 90 days and 7 more. Started Jun 2022; status: completed.
02
Drugs
udifitimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05409157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409157.